HER2+, LOW, OR ULTRALOW ADVANCED/METASTATIC BREAST CANCER

Clinical trials for HER2+, LOW, OR ULTRALOW ADVANCED/METASTATIC BREAST CANCER explained in plain language.

Never miss a new study

Get alerted when new HER2+, LOW, OR ULTRALOW ADVANCED/METASTATIC BREAST CANCER trials appear

Sign up with your email to follow new studies for HER2+, LOW, OR ULTRALOW ADVANCED/METASTATIC BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

New trial aims to ease cancer fatigue with common drug

Symptom relief Not yet recruiting

This phase 3 trial tests whether megestrol acetate, given at the start of T-DXd treatment, can prevent or lessen fatigue in 132 women with advanced breast cancer. Fatigue is a common side effect of T-DXd, and the study measures changes in fatigue scores and quality of life. Parti…

Matched conditions: HER2+, LOW, OR ULTRALOW ADVANCED/METASTATIC BREAST CANCER

Phase: PHASE3 • Sponsor: Sun Yat-sen University • Aim: Symptom relief

Last updated Apr 29, 2026 15:03 UTC

HER2+, LOW, OR ULTRALOW ADVANCED/METASTATIC BREAST CANCER

Get alerted when new HER2+, LOW, OR ULTRALOW ADVANCED/METASTATIC BREAST CANCER trials appear

New trial aims to ease cancer fatigue with common drug